Applied DNA Launches Mpox Clade I and Clade II Testing Service

STONY BROOK, NY / ACCESSWIRE / September 11, 2024 / Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, has announced the expansion of its clinical testing services. The company’s subsidiary, Applied DNA Clinical Labs, LLC (ADCL), now offers testing for both mpox Clade I and Clade II. This new service follows interactions with the New York State Department of Health (NYSDOH) and the U.S. Food and Drug Administration (FDA).

Dr. James A. Hayward, president and CEO of Applied DNA, stated that this expansion aims to improve accessibility to mpox testing. This effort will support New York and other states in mitigating the spread of the virus.

ADCL's Linea™ Mpox Virus 1.0 Assay was previously approved for detecting mpox Clade II. In August 2024, validation testing confirmed its ability to detect Clade I, which the World Health Organization recently declared a public health emergency. Testing services will be provided from ADCL's CLEP/CLIA-certified laboratory in Stony Brook, N.Y.